Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Investment Securities: 2017-2024

Historic Gains from Investment Securities for Puma Biotechnology (PBYI) over the last 5 years, with Sep 2024 value amounting to $441,430.

  • Puma Biotechnology's Gains from Investment Securities was N/A to $441,430 in Q3 2024 from the same period last year, while for Sep 2024 it was $441,430, marking a year-over-year change of. This contributed to the annual value of $581,614 for FY2023, which is 0.13% down from last year.
  • Per Puma Biotechnology's latest filing, its Gains from Investment Securities stood at $441,430 for Q3 2024, which was down 0.00% from $441,430 recorded in Q2 2024.
  • In the past 5 years, Puma Biotechnology's Gains from Investment Securities ranged from a high of $5.4 million in Q1 2021 and a low of -$1,000 during Q4 2021.
  • Over the past 3 years, Puma Biotechnology's median Gains from Investment Securities value was $441,430 (recorded in 2024), while the average stood at $380,981.
  • Per our database at Business Quant, Puma Biotechnology's Gains from Investment Securities soared by 536,298.70% in 2020 and then plummeted by 101.54% in 2021.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Gains from Investment Securities stood at $65,000 in 2020, then slumped by 101.54% to -$1,000 in 2021, then slumped by 100.02% to -$1,000 in 2022, then surged by 58,261.40% to $581,614 in 2023, then decreased by 24.10% to $441,430 in 2024.
  • Its last three reported values are $441,430 in Q3 2024, $441,430 for Q2 2024, and $441,430 during Q1 2024.